HALEON

2022 Full year results

March 2023

Disclaimer

This document contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future financial condition and performance, and so Haleon's actual results may differ materially from what is expressed or implied by such forward-looking statements. Forward-looking statements sometimes use words such as "expects", "anticipates", "believes", "targets", "plans" "intends", "aims", "projects", "indicates", "may", "might", "will", "should", "potential", "could" and words of similar meaning (or the negative thereof). All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to future actions, prospective products or product approvals, delivery on strategic initiatives (including but not limited to acquisitions and dispositions, realisations of efficiencies and responsible business goals), future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Any forward-looking statements made by or on behalf of Haleon speak only as of the date they are made and are based upon the knowledge and information available to Haleon on the date of this document. These forward-looking statements and views may be based on a number of assumptions and, by their nature, involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future and/or are beyond Haleon's control or precise estimate. Such risks, uncertainties and other factors that could cause Haleon's actual results, performance or achievements to differ materially from those in the forward-looking statements include, but are not limited to, those discussed under "Risk Factors" on pages 17 to 45 of Haleon's prospectus and under "Risk Factors" in Haleon's Registration Statement on Form 20-F. Forward-looking statements should, therefore, be construed in light of such risk factors and undue reliance should not be placed on forward-looking statements.

Subject to our obligations under English and U.S. law in relation to disclosure and ongoing information (including under the Market Abuse Regulations, the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority ("FCA")), we undertake no obligation to update publicly or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. You should, however, consult any additional disclosures that Haleon may make in any documents which it publishes and/or files with the SEC and take note of these disclosures, wherever you are located.

No statement in this document is or is intended to be a profit forecast or profit estimate.





Brian McNamara CEO


2022 Full year results

HALEON

- Extraordinary year, successfully separated and unveiled Haleon, a listed 100% consumer heath company
 - Our strategy is working, delivering strong growth with opportunities across the business for this to continue
 - **FY22 saw strong top line growth** with 6%¹ adjusted operating profit growth despite significant cost inflation, standalone costs and adverse transactional foreign exchange
 - **Continuing to evolve responsible agenda,** delivering on environmental targets and a real opportunity to make a difference in health inclusivity

Increasingly confident in medium term guidance and well placed for FY 2023

Clear approach delivering our growth ambitions







Full year results

9.0[%]

4.3%/4.7%

Organic sales growth¹

Price / volume mix

10.1[%]

Power brand growth

Q4 results

5.0[%]



Organic sales growth¹

Price / volume mix

Competitive performance: 2/3 business gained or held share²

22.8% flat on reported and down 60bps CER

Ecommerce:

Adjusted operating margin¹:

growth up mid teens percent now 9.0% of total sales

Strong free cash flow

Net debt leverage 3.6x

HALEON

1 Reconciliation of IFRS to Adjusted results can be found in the Appendix

2 Market share statements throughout this report are estimates based on the Group's analysis of third party market data of revenue for 2022 including IQVIA, IRI and Nielsen data. Represents % of brand-market combinations gaining or maintaining share (this analysis covers > 85% of Haleon's total revenue)



Outperformance: all three Power Brands gaining share

Sales growth running at c.2x the rate of overall market

5.6[%]

FY organic sales growth¹

Category held back by negative impact of Covid lockdowns in China

Winning innovations:

Sensodyne Complete Protection

new formula with superior cleaning launched in 18 markets

Polident/Poligrip Power Max Hold+

launched in 15+ markets and outperforming the category

Geo-expansion:

parodontax launch

in South Africa & India





Vitamins, mineral and supplements

Good growth despite tough H2 comparators

5.0[%]

FY organic sales growth 1

- H2 lapping new capacity coming on stream in US LY
- Broad growth across both Power and local growth brands

Growth underpinned by:

Continued new innovations

Emergen-C Kidz Caltrate Calcium Gummy Bites



Geo-expansion

Centrum launched in India (online) and Egypt



Leverage science to differentiate

Centrum Silver and COSMOS-Mind Study





Over-the-counter: Pain relief

Driving growth through agility and execution

8.9[%]

FY organic revenue growth¹

 Driven by increased incidences of flu, Covid and RSV

Panadol continuing to outperform

- Gained market share
- Agility to meet elevated consumer demand
- Successful campaigns
- New innovations such as Liquid Caps launched in Australia

Advil continued strong US performance

 Proactive work with Canadian Government to ensure Advil Kids supply during RSV surge and shortages across country





Voltaren

trend for topical consumption to be lower when analgesics higher


- Strong growth in US
- Successful campaigns





Over-the-counter: Respiratory health


Well positioned to capitalise on demand



New innovations Theraflu Max Strength launched

in Q3 in US

Commercial execution Gaining share in market









Over-the-counter: Digestive health & other

Mixed trends across three sub-segments



FY organic revenue growth¹

Growth typical run rate for category

- Digestive health faced challenging conditions in preventative antacid market which adversely impacted Nexium
- Skin health underpinned by Chapstick
- Smoking cessation declined







Performance underpinned by strong execution and financial discipline

Demerger, listing and separation	Synergies	Offsetting inflationary pressures
Successful separation Technology systems cutover complete	Delivered final Pfizer synergies taking aggregate to over £600m	Through operating leverage and driving efficiency across the business

Responsible business integral to our strategy

Environmental commitment

Continuing to progress against environmental targets set out at our Capital Markets Day in 2022

Haleon 100% powered by renewable electricity across all of our directly owned and controlled sites in 2022



Health inclusivity

Seeing AI Partnership with Microsoft to help consumers who are blind, have low vision or low literacy access essential information on our labels



Strong Governance

Corporate governance, policies and standard in place

New remuneration policy announced aligned to delivering on external commitments






Tobias Hestler CFO

2022 Full year results

2022 Delivering strong results






Strong FY revenue growth

£m

Healthy balance of volume/mix and pricing



Broad based growth across categories

Healthy balance of price and volume/mix


	FY22 Revenue		Organic	revenue g	rowth ¹			
	£m	FY	Q1	Q2	Q3	Q4		
Oral Health	2,957	5.6%	7.9%	2.0%	6.7%	5.3%		
VMS	1,675	5.0%	14.9%	9.0%	(1.4)%	(0.7)%		Q4 Decline driven by comparative
Pain Relief	2,551	8.9%	18.9%	4.9%	3.6%	8.9%		Strong cold and flu incidences in Q4,
Respiratory Health	1,579	32.6%	52.9%	39.7%	30.2%	16.2%		significantly above 2019 levels in US and Europe
Digestive Health and Other	2,096	2.9%	4.3%	2.8%	8.4%	(3.2)%		Q4 decline largely driven by sell-in in Q2
TOTAL	10,858	9.0%	15.6%	7.5%	8.1%	5.0%	_	
Price		4.3%	2.6%	4.0%	5.5%	5.0%		
Volume/Mix		4.7%	13.0%	3.5%	2.6%	-%		Flat volume in Q4:Decline in North America (additional
								supply coming on stream in 2021 and a recall at Tums which has now been
Organic growth ex. Cold and Flu	1	с. 6%	с. 11%	с. 4%	с. 5%	с. 3%		resolved)Lower volumes in Russia



Respiratory

Q4 cold and flu incidences ahead of 2019 and 2021 levels


Weekly US market cold and flu sales (\$m)



VMS – Underlying consumption remains strong


Recent modest growth declines are driven by lapping strong demand in 2021 from both Delta and Omicron variants

Haleon plays in a sub-set of VMS growing ahead of the overall VMS market




Source: N. Hall (2021), Haleon data

Composition of global VMS market



Strong revenue growth across regions



Revenue

North America 5.9% OSG¹ £4,116m (2021: £3,525m)

EMEA & LATAM 10.9% OSG¹ £4,270m (2021: £3,877m)

Asia Pacific **10.6%** osg¹ £2,472m (2021: £2,143m)



1 Refers to Organic revenue growth; Reconciliation of IFRS to Adjusted results can be found in the Appendix

North America

Healthy balance of price and volume/mix

2.9[%]

Price

5.9%

Organic growth¹

£4,116^m

26.0%

Adjusted

3.0[%]

Volume / mix

Sales



• **FY organic growth**¹: 5.9% with 2.9% price and 3.0% volume/mix

• **Q4 organic growth**¹: 1.6% with 3.0% price and (1.4)% volume/mix

- Decline in Q4 volume/mix reflects:
 - Tough comparative from supply in VMS and Pain Relief coming on stream
 - Changes in retailer stocking patterns from Sensodyne and across Smokers Health
 - A recall of a Tums SKU (now resolved)

• FY Adjusted operating margin¹ increased 130bps (CER):

- + Pricing
- + Cost management
- Commodity and freight headwinds
- Standalone costs

21

EMEA & LATAM

Strong organic growth helped by pricing

10.9[%]

Sales



Price



Volume / mix

Organic growth $^{\scriptscriptstyle 1}$

£4,270^m



Adjusted operating margin¹



- **FY organic growth**¹: 10.9% with 6.4% price and 4.5% volume/mix
- **Q4 organic growth**¹: 6.8% with 8.8% price and (2.0)% volume/mix
- Decline in Q4 volume/mix reflects:
 - Lower volumes in Russia
 - High comparative base in Respiratory Health

• FY Adjusted operating margin¹ decreased 200bps (CER):

- + Pricing
- + Cost management
- Higher commodity and freight costs
- Adverse transactional FX
- Standalone costs



Asia Pacific

Organic growth driven by strong volume growth

8.0[%]

Volume / mix

10.6[%]

Sales

Organic growth¹

£2,472^m

20.5%

2.6[%]

Price

Adjusted operating margin¹



• FY organic growth¹: 10.6% with 2.6% price and 8.0% volume/mix

- **Q4 organic growth**¹: 8.3% with 1.5% price and 6.8% volume/mix
- Q4 organic growth¹ reflects:
 - Lower pricing than other regions given lower inflationary environment and price controls on certain brands
 - Strong volume helped by Covid related demand

• FY Adjusted operating margin¹ declined 120bps (CER):

- + Strong operating leverage
- + Cost management
- Higher freight costs
- A&P investment
- Standalone costs



Adjusted operating profit growth of 6% constant currency


£m	FY 2022	FY 2021	% change					
Revenue	10,858	9,545	13.8		Power brand organic revenue growth ahead of Haleon organic growth (10.1%)			
Adjusted gross profit ¹	6,772	6,002	12.8					
% Adjusted gross margin ¹	62.4%	62.9%	(0.5)pts		Cost inflation largely offset by pricing			
Sales, general and admin ¹	(4,001)	(3,582)	11.7]	£0.2bn of standalone costs, R&D impacted by re-			
Research and development ¹	(303)	(248)	22.2 _	∫ ← − −	allocation of spend from SG&A			
Adjusted operating profit ¹	2,472	2,172	13.8	· 	+5.9% at CER			
% Adjusted operating margin	22.8%	22.8%	-	←	(60) bps at CER with c. 30bps drag from			
Depreciation and amortisation ²	258	241	7.1	•	transactional FX movements			
Adjusted EBITDA ¹	2,730	2,413	13.1					

1 Reconciliation of IFRS to Adjusted results can be found in the Appendix



2 Includes Depreciation – Property Plant and Equipment £142m (FY 2021: £139m), Depreciation – Right of Use Assets: £38m (FY 2021: £35m), Amortisation – Computer Software: £64m (FY 2021: £54m), Impairment – Property Plant and Equipment, Right of Use assets and Computer Software: £14m (FY 2021: £13m)

Navigating cost inflation with positive operating leverage



- Standalone costs at the upper end of £0.2bn guided range
- Over delivery of Pfizer synergies (>£0.6bn annualised delivered)
- A&P flat (CER) reflecting successful efficiency focus and Russia impact; Consumer facing A&P spend ex. Russia up 6% (CER)
- Increase in material costs and freight to ship

HALEON ¹ Reconciliation of IFRS to 2 Calculated impact based

3% Adjusted EPS growth driven by strong operating profit, offset by interest costs

£m	FY 2022	FY 2021	% change
Adjusted operating profit ¹	2,472	2,172	13.8
Net finance costs	(207)	(2)	n/m 🗸
Adjusted tax ¹	(506)	(469)	7.9
% tax rate	22.3%	21.6%	0.7
Adjusted profit after tax ¹	1,759	1,701	3.4
Non controlling interests	(59)	(49)	20.4
Profit after tax attributed to shareholders of the Group ¹	1,700	1,652	2.9
Adjusted Diluted EPS	18.4p	17.9p	2.8

Reflects interest of £258m related to bonds issued in March 2022 offset by interest income of £51m mainly related to the on-lend of funds to GSK and Pfizer



Adjusting items largely non-cash impairment, separation and admission costs

£m	FY 2022	FY 2021	% change	
Adjusted operating profit ¹	2,472	2,172	13.8	
Net amortisation and impairment of intangible assets ²	(172)	(16)	4	Includes £129m impairment related to a Preparation-H and a small brand in the Ukraine
Restructuring costs ²	(41)	(195)	4	Okraine
Transaction related costs	(8)	-		Charges largely related to Pfizer integration
Separation and admission costs ²	(411)	(278)	-	Peak separation and admission costs in 2
Disposals and others ²	(15)	(45)	<	2022 includes provision for settlement of
Operating profit ³	t ³ 1,825 1,638 11.4	claims and small disposal income		
% Operating margin ³	16.8%	17.2%	(0.4)ppts	

Strong free cash flow generation

£m	FY 2022	FY 2021		
Adjusted operating profit ¹	2,472	2,172	_	
P&L adjusting items ²	(647)	(534)		Separation and admission costs peaked in 2022 an
Non-cash movements ³	424	216		a non-cash impairment charge
Working capital and other movements ⁴	138	(188)	◄	Working capital management in 2022
Taxation paid	(324)	(310)	←	2022 cash tax benefitted from refunds in prior year
Net interest (paid)/received	(144)	1		2022 bond coupon paid in arrears
Distribution to non-controlling interests	(48)	(35)	◄	Largely reflects performance of China JV with TSK8
Net capital expenditure ⁵	(292)	(149)		2021 includes £149m of disposal proceeds (2022:
Free cash flow	1,579	1,173	_	£36m)

1 Reconciliation of IFRS to Adjusted results can be found in the Appendix

2 Adjusting items include Net amortization and impairment of intangible assets: £172m (2021: £16m), Restructuring costs: £41m (2021: £195m), Transaction Related Costs: £8m (2021: nil), Separation and admission costs: £411m (2021: £278m), Disposals and Others: £15m (2021: £45m)


3 Includes Depreciation of property, plant and equipment and rights of use assets: £180m (2021: £174m), Amortisation of intangible assets: £107m (2021: £94m), Impairment and assets written off, net of reversals: £143m (2021: £1m), Profit on sale of intangible assets: £(30)m (2021: £(27)m, Profit on sale of businesses: Nil (2021: £(4)m), and Other non-cash movements: £24m (2021: £(22)m)

4 Includes decrease in working capital: £50m (2021: £121m), increase in other net liabilities: £88m (2021: £(309m))

5 Includes purchase of property, plant and equipment: £(304)m (FY 2021: £(228)m), Proceeds from sale of property, plant and equipment: £-m (FY 2021: £12m), Purchase of intangible assets: £(24)m (FY 2021: £(70)m) and Proceeds from sale of intangible assets: £36m (FY 2021: £137m)



Debt reduction since demerger



c.3.1%

Cost of debt

87%/13%

Fixed/floating¹

7.8 years

Duration²

£2.5^{bn}

Liquidity³

No major refinancing

Until 2025

2 Weighted average time to maturity for bond debt as at 31st December 2022

3 At 31st December 2022, comprising £2.2bn (\$1.4bn and £1.0bn) of undrawn bank facilities, £0.3bn of Commercial Paper issuance and £0.6bn of cash and cash equivalents

4 Definitions of adjusted measures can be found in the Appendix

Outlook for full year 2023

Organic revenue growth¹ of 4-6%

Adjusted operating profit margin¹ broadly flat

(FY 2022: 22.8%) after absorbing c.40 bps adverse transactional foreign exchange impact based on current market rates²

Net interest expense c. £350m

Adjusted effective tax rate¹ 23-24%



HALEON

- Extraordinary year, successfully separated and unveiled Haleon, a listed 100% consumer heath company
 - Our strategy is working, delivering strong growth with opportunities across the business for this to continue
 - **FY22 saw strong top line growth** with 6%¹ adjusted operating profit growth despite significant cost inflation, standalone costs and adverse transactional foreign exchange
 - **Continuing to evolve responsible agenda,** delivering on environmental targets and a real opportunity to make a difference in health inclusivity

Increasingly confident in medium term guidance and well placed for FY 2023

HALEON



Appendix

2022 Full year results


Glossary

A number of Adjusted measures are used to report the performance of our business which are non-IFRS measures. Adjusted results, CER and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. These measures are defined and set out below. Reconciliations to the nearest IFRS measure will be provided as part of the Historical Financial Information as part of the Prospectus.

Adjusted EBITDA is defined as profit after tax for the year excluding income tax, finance income, finance expense, Adjusting Items (as defined below), depreciation of property plant and equipment, impairment of property plant and equipment net of reversals, depreciation of right-of-use assets, and amortisation of software intangibles.

Adjusting Items include the following:

- Net amortisation and impairment of intangible assets: Net impairment of intangibles, impairment of goodwill and amortisation of intangibles excluding computer software. Intangible amortisation and impairments arising from intangibles acquired in business combinations are adjusted to reflect the performance of the business excluding the effect of acquisition accounting
- **Restructuring costs:** Include personnel costs associated with restructuring programmes, impairments of tangible assets and computer software relating to specific programmes approved by the Board of the Company from time to time that are structural and of a significant scale.
- Separation and admission costs: Costs incurred in relation to and in connection with Separation, UK Admission and registration of the Company's Ordinary Shares represented by the Company's American Depositary Shares ("ADSs") under the Exchange Act and listing of ADSs on the NYSE (the "US Listing"). These costs are not directly attributable to the sale of the Group's products and specifically relate to the foregoing activities, affecting comparability of the Group's financial results in historical and future reporting periods.
- **Transaction related costs:** Transaction-related accounting or other adjustments related to significant acquisitions and including deal costs and other pre- acquisition costs when there is certainty that an acquisition will complete. It also includes costs of registering and issuing debt and equity securities and the effect of inventory revaluations on acquisitions.
- **Disposal and other adjusting items:** Gains and losses on disposals of assets, businesses and tax indemnities related to business combinations. Legal settlement and judgements, impact of changes in tax rates and tax laws on related deferred tax assets and liabilities, retained or uninsured losses related to acts of terrorism, product recalls, natural disasters and



Adjusted Operating Profit is defined as operating profit less Adjusting Items as defined earlier.

Free cash flow Free cash flow is calculated as net cash inflow from operating activities plus cash inflows from the sale of intangible assets, the sale of property, plant and equipment and interest received, less cash outflows for the purchase of intangible assets, the purchase of property, plant and equipment, distributions to non-controlling interests and interest paid.

Free cash flow conversion is defined as free cash flow, as defined above, divided by profit after tax.

Net capital expenditure includes purchases net of sales of property, plant and equipment and other intangible assets.

Net debt: Net debt at a period end is calculated as short-term borrowings (including bank overdrafts and short-term lease liabilities), long-term borrowings (including long-term lease liabilities), and derivative financial liabilities less cash and cash equivalents and derivative financial assets, liabilities less cash and cash equivalents and derivative financial assets.

Organic revenue growth represents revenue growth, as determined under IFRS and excluding the impact of acquisitions, divestments and closures of brands or businesses, revenue attributable to manufacturing service agreements ("MSAs") relating to divestments and the closure of sites or brands, and the impact of currency exchange movements.

Organic revenue growth by individual region is further discussed by price and volume/mix changes, which are defined as follows:

- **Price:** Defined as the variation in revenue attributable to changes in prices during the period. Price excludes the impact to organic revenue growth due to (i) the volume of products sold during the period and (ii) the composition of products sold during the period. Price is calculated as current year net price minus prior year net price multiplied by current year volume. Net price is the sales price, after deduction of any trade, cash or volume discounts that can be reliably estimated at point of sale. Value added tax and other sales taxes are excluded from the net price.
- **Volume/Mix:** Defined as the variation in revenue attributable to changes in volumes and composition of products in the period



Medium term guidance

Organic annual sales growth of 4-6%¹

Sustainable moderate adjusted operating margin expansion at constant currency¹ per annum

Net debt/EBITDA² **expect to be below 3x** during 2024



– Considerations on phasing of growth

Comments on 2022 performance (unless otherwise stated)

	2022 % of revenue	Q1	Q2	Q3	Q4
Oral Health	27%	 ERP pull forward 	 Reversal of ERP pull forward Rebound from China lockdown 	-	 Reduction in inventories at major retailers
VMS	15%	 Benefit from Omicron wave 	-	-	-
Pain Relief	24%	 Benefit from Omicron wave Strong cold and flu start to 2023 	-	-	 Comparative from strong cold and flu season
Respiratory Health	15%	 Strong cold and flu start to 2023 ERP pull forward 	Reversal of ERP pull forward	Too early to predict if out of season consumption from Covid remains	 Comparative from strong cold and flu season
Digestive Health and Other	19%	_	-	 Sell in ahead of Q4 	 Reversal of sell in and reduction in inventories at Smokers Health
Price (FY22)		+2.6%	+4.0%	+5.5%	+5.0%

HALEON

Full Year 2022 translational currency impact

Currency	2022 currency as % of total revenue	Average 2021	Average 2022	Spot 10.2.23
USD	33%	1.38	1.24	1.21
EUR	16%	1.16	1.17	1.13
CNY	8%	8.86	8.31	8.22
Others*	43%	100	98	100
Total	100%			

* Index basket of currencies represents the movement in 2022 vs 2021 assuming 100 for average 2021 rates

- Estimated positive translational foreign exchange impact
 - c. +1.0% on revenue
 - c. +1.5% on adjusted operating profit

Assuming exchange rates as of 10 February 2023 were to hold for the remainder of the year and using FY22 results as a base.



IFRS and Adjusted Income Statement

Unaudited

2022 £m	IFRS Results	Net amortisation and impairment of intangible assets ¹	Restructuring costs ²	Transaction -related costs ³	Separation and Admission costs ⁴	Disposals and others ⁵	Adjusted Results
Revenue	10,858	_	_	_	_	_	10,858
Gross profit	6,577	172	19	-	4	-	6,772
Gross profit margin %	60.6%						62.4%
Operating profit	1,825	172	41	8	411	15	2,472
Operating profit margin %	16.8%						22.8%
Net finance costs	(207)	-	_	_	_	_	(207)
Profit before tax	1,618	172	41	8	411	15	2,265
Income tax	(499)	(37)	(7)	(2)	(55)	94	(506)
Effective tax rate %	31%						22%
Profit after tax for the year	1,119	135	34	6	356	109	1,759
Profit attributable to shareholders	1,060	135	34	6	356	109	1,700
Diluted earnings per share (pence)	11.5	1.4	0.4	0.1	3.8	1.2	18.4
Weighted average number of shares (diluted) (millions)	9,239						9,239

2021 £m	IFRS Results	Net amortisation and impairment of intangible assets ¹	Restructuring costs ²	Transaction -related costs ³	Separation and Admission costs ⁴	Disposals and others ⁵	Adjusted Results
Revenue	9,545	_	_	_	_	_	9,545
Gross profit	5,950	8	44	-	-	_	6,002
Gross profit margin %	62.3%						62.9%
Operating profit	1,638	16	195	_	278	45	2,172
Operating profit margin %	17.2%						22.8%
Net finance costs	(2)	-	—	-	-	_	(2)
Profit before tax	1,636	16	195	-	278	45	2,170
Income tax	(197)	8	(36)	_	(47)	(197)	(469)
Effective tax rate %	12%						22%
Profit after tax for the year	1,439	24	159	_	231	(152)	1,701
Profit attributable to shareholders	1,390	24	159	_	231	(152)	1,652
Diluted earnings per share (pence)	15.1	0.2	1.7	_	2.5	(1.6)	17.9
Weighted average number of shares (diluted) (millions)	9,235						9,235

- 1. Net amortisation and impairment of intangible assets: includes impairment of intangible assets (2022: £129m, 2021: £12m), reversal of impairment (2022: £nil, 2021: £(36)m) and amortisation of intangible assets excluding computer software (2022: £43m, 2021: £40m).
- 2. Restructuring costs: includes amounts related to business transformation activities.
- 3. Transaction-related costs: includes amounts related to acquisition of a manufacturing site.
- Separation and Admission costs: includes amounts incurred in relation to and in connection with the separation and listing of the Group as a standalone business.
- 5. Disposals and others: includes net gains on disposals of assets and business changes (2022: $\pounds(20)m$), 2021: $\pounds(31)m$), offset by other items including a provision for PPI litigation taken in 2022. In addition, it includes tax indemnities related to business combinations (2021: $\pounds76m$). The 2022 tax effect includes $\pounds102m$ tax charge related to the revaluation of US deferred tax liabilities due to the increase in the blended rate of US state taxes expected to apply as a result of the demerger. The 2021 tax effect includes a $\pounds164m$ tax credit related to the uplift of the tax basis of certain intra-group brand transfers.

Reconciliation of FY organic growth

Product Categories

2022 vs 2021 (%)	Oral Health	VMS	Pain Relief	Respiratory Health	Digestive Health and Others	Total
Revenue Growth	8.6	11.6	14.0	39.5	7.4	13.8
Organic Adjustments	(0.3)	(0.2)	(0.4)	0.0	2.2	0.2
of which:						
Effect of Acquisitions	(0.3)	(0.3)	(0.5)	-	-	(0.3)
Effect of Disposals	-	0.1	0.1	-	0.8	0.2
Effect of MSAs	-	-	-	-	1.4	0.3
Effect of Exchange Rates	(2.7)	(6.4)	(4.7)	(6.9)	(6.7)	(5.0)
Organic Revenue Growth	5.6	5.0	8.9	32.6	2.9	9.0

Geographical Segments

	EMEA and		
North America	LatAm	APAC	Total
16.8	10.1	15.4	13.8
0.3	0.9	(1.0)	0.2
-	-	(1.1)	(0.3)
0.1	0.4	-	0.2
0.2	0.5	0.1	0.3
(11.2)	(0.1)	(3.8)	(5.0)
5.9	10.9	10.6	9.0
2.9	6.4	2.6	4.3
3.0	4.5	8.0	4.7
	16.8 0.3 - 0.1 0.2 (11.2) 5.9 2.9	North America LatAm 16.8 10.1 0.3 0.9 - - 0.1 0.4 0.2 0.5 (11.2) (0.1) 5.9 10.9 2.9 6.4	North America LatAm APAC 16.8 10.1 15.4 0.3 0.9 (1.0) - - (1.1) 0.1 0.4 - 0.2 0.5 0.1 (11.2) (0.1) (3.8) 5.9 10.9 10.6

Reconciliation of quarterly organic growth

North America 2022 vs 2021 (%)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022
Revenue Growth	20.1	15.0	18.5	14.1	16.8
Organic Adjustments	0.8	0.1	0.1	0.3	0.3
of which:					
Effect of Acquisitions		-	-	-	-
Effect of Disposals	0.5	-	-	-	0.1
Effect of MSAs	0.3	0.1	0.1	0.3	0.2
Effect of Exchange Rates	(3.6)	(11.2)	(15.7)	(12.8)	(11.2)
Organic Revenue Growth	17.3	3.9	2.9	1.6	5.9

EMEA & LatAm

2022 vs 2021 (%)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022
Revenue Growth	8.0	10.1	13.1	9.8	10.1
Organic Adjustments	2.0	1.1	0.6	(0.1)	0.9
of which:					
Effect of Acquisitions	-	-	-	-	-
Effect of Disposals	1.1	0.6	0.2	(0.1)	0.4
Effect of MSAs	0.9	0.5	0.4	-	0.5
Effect of Exchange Rates	4.5	(1.0)	(1.5)	(2.9)	(0.1)
Organic Revenue Growth	14.5	10.2	12.2	6.8	10.9

HALEON

Reconciliation of quarterly organic growth

ΑΡΑϹ					
2022 vs 2021 (%)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022
Revenue Growth	15.8	15.4	17.6	12.2	15.4
Organic Adjustments	0.2	(1.4)	(1.3)	(1.9)	(1.0)
of which:					
Effect of Acquisitions	-	(1.4)	(1.5)	(1.7)	(1.1)
Effect of Disposals	-	-	-	-	-
Effect of MSAs	0.2	-	0.2	(0.2)	0.1
Effect of Exchange Rates	(0.8)	(4.5)	(7.3)	(2.0)	(3.8)
Organic Revenue Growth	15.2	9.5	9.0	8.3	10.6

Group

2022 vs 2021 (%)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022
Revenue Growth	13.9	12.9	16.1	12.0	13.8
Organic Adjustments	1.2	0.1	-	(0.3)	0.2
of which:					
Effect of Acquisitions	-	(0.3)	(0.3)	(0.3)	(0.3)
Effect of Disposals	0.6	0.2	0.1	(0.1)	0.2
Effect of MSAs	0.6	0.2	0.2	0.1	0.3
Effect of Exchange Rates	0.5	(5.5)	(8.0)	(6.7)	(5.0)
Organic Revenue Growth	15.6	7.5	8.1	5.0	9.0



– Free cash flow

Free cash flow

Ти	velve months	to 31 Dec
£m	2022	2021
Net cash inflow from operating activities	2,063	1,356
Less: Net capital expenditure	(292)	(149)
Less: Distributions to non-controlling interests	(48)	(35)
Less: Interest paid	(163)	(15)
Add: Interest received	19	16
Free cash flow	1,579	1,173

Free cash flow conversion

	Twelve months to 31 Dec		
£m	2022	2021	
Free cash flow	1,579	1,173	
Reported profit after tax	1,119	1,439	
Free cash flow conversion	141%	82%	



Debt profile

Net debt

£m	Group net debt at 31 Dec 2022	Group net debt at 18 July 2022 ³	
Short-term borrowings	437	332	
Long-term borrowings	10,003	11,433	
Derivative financial liabilities	206	66	
Cash and cash equivalents and liquid investments	(684)	(978)	
Derivative financial assets	(94)	(146)	
Net debt	9,868	10,707	

c.7.8 years

Duration¹

c.3.1%

Cost of debt²

£9.9^{bn}

Net debt as of Dec 2022



HALEON

2022 full year results

Sonya Ghobrial

Head of Investor Relations

Sonya.x.Ghobrial@Haleon.com +44 7392 784784

Rakesh Patel

Director

Rakesh.x.Patel@Haleon.com +44 7552 484646

Emma White

Emma.x.White@Haleon.com +44 7823 523562